{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086275","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.768236+00:00","generated_at":"2026-05-31T12:11:50.292644+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Precigen reports $19.5M cash, $32.9M impairment, $30M offering, >20% workforce cut","bullets":["Preliminary cash $19.5M at June 30, 2024; non-cash impairment charges ~$32.9M and severance ~$3.0M in Q2/Q3.","Strategic pivot to PRGN-2012 gene therapy; rolling BLA submission expected H2 2024; ActoBio subsidiary shutdown.","Commences $30M underwritten public offering (plus $4.5M option); expects net proceeds plus cash to fund ops into early 2025.","Workforce reduced >20%; PRGN-2009 non-NCI sites paused; UltraCAR-T programs paused except PRGN-3006; preclinical halted.","PRGN-2012 confirmatory trial initiated; commercial readiness led by new CCO; revenue not reported (pre-revenue stage)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086275","json":"https://secwatch.observer/filing/0001104659-24-086275.json","markdown":"https://secwatch.observer/filing/0001104659-24-086275.md","text":"https://secwatch.observer/filing/0001104659-24-086275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000110465924086275/0001104659-24-086275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000110465924086275/tm2418396d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:11:50.292644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}